The rise of host-directed therapy has further intensified interest in developing Rho protein-based antiviral drugs tailored to specific virus types and infection stages [187], but identifying multiantigen antiviral-host targets is extremely difficult when complete information about the human genome/kinase set is not available. Here, RHO is linked to infection.